Webcast FDA's LDT Proposed Rule: A Discussion

FDA's LDT Proposed Rule: A Discussion

 · US/Eastern

About This Webcast

On September 29, 2023, the Food and Drug Administration (FDA) released a new proposed rule outlining the regulation of laboratory-developed tests (LDTs) as medical devices. Unlike past proposals, the FDA has taken a simple approach: laboratories developing LDTs for clinical use are manufacturing in vitro diagnostic medical devices (IVDs) for commercial distribution, and therefore, must eventually comply with FDA’s already-established IVD requirements. In this webinar, Epstein Becker Green attorneys James Boiani and Megan Robertson explore subjects such as the FDA’s proposed regulatory amendment, the phaseout policy applicable to IVDs manufactured and offered as LDTs, and the minimum added requirements for LDTs as medical devices.

Speakers

James A. Boiani

James A. Boiani

Member of the Firm , Epstein Becker Green

Attorney James Boiani has extensive experience in FDA and CLIA legal and regulatory matters, having worked with large and small medical device companies (including many in vitro diagnostic companies), pharmaceutical companies, clinical laboratories, and trade associations in the life sciences industry on a variety of FDA- and CLIA-related issues. Read more >

Megan Robertson

Megan Robertson

Associate , Epstein Becker Green

Attorney Megan Robertson regularly advises lab clients and stakeholders on state and federal compliance considerations. Megan is experienced in guiding clients through the development of direct access testing business models, including aspects such as corporate structure, risk management, and regulatory compliance. Read more >